Ebola Vaccine Using Immunovaccine’s DepoVax Proves Highly Efficacious in Non-Human Primate Study

Ebola Vaccine Using Immunovaccine’s DepoVax Proves Highly Efficacious in Non-Human Primate Study August 25th, 2014 Immunovaccine Inc. (“Immunovaccine”) (TSX-V: IMV), a clinical stage vaccine company, today announced positive results for a vaccine formulated in its DepoVax™ technology in an Ebola virus challenge study performed by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). …

Immunovaccine’s DepoVax™ Technology Underpins New Experimental Therapy for Cervical, Head and Neck Cancers

IMV vaccine adjuvant technology of choice For Dana-Farber’s HPV-related cancer clinical trial  April 8, 2014 Immunovaccine Inc., a clinical stage vaccine company, today announced that its DepoVax™ adjuvanting technology will underlie the design of a new cancer vaccine trial that will be conducted by the Dana-Farber Cancer Institute to treat cervical and head and neck cancer. In a competitive process, …

Immunovaccine Highlights Enhanced Anti-Tumor Activity of Cancer Vaccine Combination Therapies in Presentation at the 2014 AACR Annual Meeting

Study findings show enhanced therapeutic potential for vaccine when combined with cyclophosphamide and the checkpoint inhibitor anti-PD-1 April 7, 2014 Immunovaccine Inc., a clinical stage vaccine company, presented positive data from clinical and preclinical vaccine studies, including DPX-Survivac, the company’s lead therapeutic cancer vaccine, this weekend at the American Association for Cancer Research (AACR) 2014 Annual Meeting. In a poster …

Immunovaccine and Pfenex Report Positive Results From Single Dose Anthrax Vaccine Studies

Data demonstrates 100% protection against a lethal anthrax challenge in animals after vaccination with as little as 0.33 microgram of mutant recombinant Protective Antigen; Dose response observed in the first 28 days following vaccination April 1, 2014 Immunovaccine Inc. and Pfenex Inc. today announced positive results from anthrax challenge studies in rabbits using Pfenex’s mutant recombinant Protective Antigen (mrPA) formulated …